Aptus Capital Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History
Bought
Maintained
Sold
Other funds holding PPH
Aptus Capital Advisors's PPH Position: Q3 2026 in Review
Aptus Capital Advisors increased its VanEck Pharmaceutical ETF (PPH) stake by 0.51% in Q3 2026, buying an estimated $334 and bringing the position to 587 shares worth $64.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1342.
Aptus Capital Advisors first reported a position in PPH in Q1 2024 and has held it in 11 quarters since. The position peaked at $98K in Q3 2024. 154 funds tracked by Wall St. Rank hold PPH as of Q3 2026.
- Aptus Capital Advisors held 587 shares of VanEck Pharmaceutical ETF worth $64.3K as of Q3 2026.
- Aptus Capital Advisors bought 3 VanEck Pharmaceutical ETF shares in Q3 2026, an estimated $334.
- VanEck Pharmaceutical ETF made up ﹤0.01% of Aptus Capital Advisors's portfolio in Q3 2026, its #1342 holding.
- Aptus Capital Advisors first reported a position in VanEck Pharmaceutical ETF in Q1 2024 and has held it in 11 quarters since.
- Aptus Capital Advisors's VanEck Pharmaceutical ETF position peaked at $98K in Q3 2024.
- 154 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2026.
Based on Aptus Capital Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.